CONDITION

Mixed connective tissue disease

Mixed connective tissue disease is an autoimmune condition with features of lupus, systemic sclerosis, and inflammatory muscle disease.

WHAT IT IS
Autoimmune overlap condition affecting connective tissues and organs

BODY SYSTEM
Joints, muscles, skin, lungs, heart, and digestive tract

MAIN SYMPTOMS
Raynaud phenomenon, swollen hands, joint pain, muscle weakness

WHAT CAUSES IT
Misguided immune activity; exact trigger unknown

HOW IT IS DIAGNOSED
Clinical pattern plus high anti-U1 RNP antibody levels

MAIN TREATMENT
Immune-suppressing and symptom-targeted medicines

CAN IT BE CURED?
No, treatment controls rather than cures

IS IT AN EMERGENCY?
Sometimes, sudden breathing trouble or chest pain

LONG-TERM OUTLOOK
Often manageable, but lung or heart complications can be serious

Overview

Mixed connective tissue disease, or MCTD, is a long-term autoimmune condition. In autoimmune conditions, the immune system mistakenly attacks the body's own tissues.

MCTD has a mixture of features seen in three other autoimmune conditions:

Some people also have features of rheumatoid arthritis. This mixture is why MCTD is sometimes called an "overlap" condition.

Connective tissue supports and binds structures throughout the body. Because it is widespread, MCTD can affect the joints, muscles, skin, blood vessels, lungs, heart, and digestive tract. The pattern is different from person to person and may change over time.

Nearly everyone diagnosed with MCTD has a high level of an antibody called anti-U1 RNP. An

antibody is a protein made by the immune system. This antibody supports the diagnosis, but it does not confirm MCTD by itself. Some people with lupus or another autoimmune condition also have it.

MCTD matters because inflammation can sometimes affect the lungs or the blood vessels carrying blood through the lungs. Regular follow-up helps find these complications before they cause obvious symptoms.

- Systemic lupus erythematosus, often called lupus
- Systemic sclerosis, also called scleroderma
- Inflammatory myositis, which causes muscle inflammation and weakness

Symptoms

Symptoms may appear gradually rather than all at once. Early symptoms can be general, such as tiredness, joint aches, or a mild fever. These symptoms have many possible causes and do not mean that you have MCTD.

Raynaud phenomenon is a common early feature. Fingers or toes change colour in response to cold or stress. They may become white or blue before turning red as blood flow returns. The area can feel numb, painful, or tingly.

Other possible symptoms include:

Muscle weakness is different from tiredness. It may make it difficult to climb stairs, rise from a chair, lift objects overhead, or wash your hair.

Symptoms often come and go. A period when inflammation and symptoms increase is called a flare. A quieter period may be called remission, although some symptoms, such as Raynaud phenomenon or reflux, can continue between flares.

- Puffy or swollen fingers and hands
- Painful, stiff, or swollen joints
- Muscle weakness, especially around the shoulders or hips
- Rashes or skin that becomes unusually tight or thick
- Heartburn, reflux, or trouble swallowing
- Shortness of breath, cough, or reduced exercise capacity
- Mouth ulcers, hair thinning, or sensitivity to sunlight
- Chest pain that becomes worse with a deep breath

Causes and risk factors

The exact cause of MCTD is unknown. It develops when the immune system becomes misdirected and causes inflammation in connective tissue and organs.

Genes may influence susceptibility, but MCTD is not usually passed directly from parent to child in a predictable way. Having a relative with an autoimmune condition does not mean that you will develop MCTD.

Possible environmental or hormonal influences have been studied, but no single infection, food, medication, or lifestyle choice has been shown to cause the condition. MCTD is diagnosed more often in women, although people of any sex and age can develop it.[1,2]

Diagnosis

There is no single test that confirms MCTD. Diagnosis is based on your symptoms, examination findings, antibody results, and evidence that different organs are involved. It may take time for the characteristic pattern to become clear.

Blood tests usually include an antinuclear antibody, or ANA, test. A positive ANA means antibodies are reacting with material inside cells. It is common in autoimmune conditions but can also occur in healthy people.

A high anti-U1 RNP antibody level is an important part of the diagnosis. However, this result alone is not enough. Clinicians use diagnostic or classification criteria that combine it with features such as Raynaud phenomenon, swollen hands, arthritis, muscle inflammation, or skin changes.[2,3]

Other tests may check for inflammation and organ involvement:

The results also help distinguish MCTD from lupus, systemic sclerosis, inflammatory myositis, rheumatoid arthritis, and other causes of similar symptoms. Some people initially described as having MCTD later develop a clearer pattern of one of these conditions.

- A full blood count to look for anaemia or low blood cell levels
- Muscle enzyme tests for evidence of muscle injury
- Kidney and liver blood tests
- Urine tests for blood or protein
- Lung function tests to measure airflow and oxygen transfer
- An echocardiogram, an ultrasound scan of the heart

- A chest CT scan when lung inflammation or scarring is suspected
- An electrocardiogram, or ECG, to check heart rhythm and activity

Treatment and management

There is no cure for MCTD, but treatment can control inflammation, relieve symptoms, protect organs, and maintain day-to-day function. Treatment is matched to the organs affected and how active the inflammation is.

Mild joint or muscle symptoms may be managed with pain-relieving or anti-inflammatory medicines. Hydroxychloroquine, an immune-modifying medicine also used for lupus, may help some skin and joint symptoms. It requires regular eye monitoring because long-term use can rarely affect the retina at the back of the eye.

Corticosteroids like prednisone or hydrocortisone can reduce inflammation quickly. The dose and length of treatment are chosen carefully because longer or higher-dose treatment can cause infection, bone thinning, raised blood pressure, diabetes, and other problems.

Other medicines that reduce immune activity may be used when symptoms continue or an organ is at risk. These include conventional immune-suppressing medicines and, in selected situations, biologic treatments. The choice depends on whether MCTD is affecting the joints, muscles, lungs, heart, or another organ.[1,2]

Raynaud phenomenon may improve by keeping the whole body warm and avoiding abrupt temperature changes. Medicines that relax blood vessels may be considered when attacks are frequent, painful, or causing skin sores.

Reflux may be managed with meal adjustments and acid-reducing medicine like omeprazole or lansoprazole . Trouble swallowing may need assessment because the muscles that move food through the oesophagus can be affected.

Pulmonary hypertension means high pressure in the blood vessels of the lungs. It requires specialist assessment and medicines aimed at those blood vessels. Interstitial lung disease, which causes inflammation or scarring within the lungs, may require immune-suppressing treatment and regular breathing tests.[4]

Treatment can affect infection risk, bones, blood counts, the liver, kidneys, or pregnancy. Monitoring may include blood tests, vaccinations, eye examinations, and bone-health checks. Do not stop corticosteroids suddenly unless a clinician has specifically advised you to do so.

Complications

MCTD does not affect everyone in the same way. Some people mainly have Raynaud phenomenon and joint symptoms. Others develop organ complications that need closer monitoring.

Pulmonary hypertension is one of the most important complications. It can cause increasing shortness of breath, chest discomfort, dizziness, fainting, or ankle swelling. It may develop gradually, which is why lung function tests and heart ultrasound scans may be recommended even when symptoms are mild.[2,4]

Interstitial lung disease can cause a dry cough, breathlessness, and reduced stamina. Lung changes range from mild and stable to progressive scarring.

Other possible complications include:

Immune-suppressing treatment can increase susceptibility to infection. Corticosteroids may also weaken bones over time. These are treatment risks rather than direct effects of MCTD, and monitoring can reduce their impact.

- Sores on the fingers from reduced blood flow
- Ongoing reflux, swallowing difficulty, or food entering the airway
- Inflammation around the heart or lungs
- Heart rhythm or heart muscle problems
- Significant muscle weakness
- Low blood cell levels
- Kidney or nervous system involvement, which is less typical but possible

Prevention

MCTD cannot currently be prevented. There is no proven diet, supplement, screening test, or lifestyle change that stops it from developing.

If you already have MCTD, you can take steps to reduce symptom triggers and support long-term health. Protecting your hands and feet from cold can reduce Raynaud attacks. Avoiding smoking is especially important because it narrows blood vessels and harms the lungs and heart.

Regular follow-up, recommended vaccinations, physical activity suited to your abilities, and taking medicines as agreed can help lower the risk of avoidable complications. Sun protection may help if sunlight triggers rashes or other lupus-like symptoms.

Living with it and what to expect

MCTD usually continues for years and requires ongoing follow-up. Its course is not predictable from a single blood result. Anti-U1 RNP antibody levels do not reliably show how active the condition is.

Symptoms can change over months or years. Joint inflammation may settle while Raynaud phenomenon continues. Some people have long quiet periods between flares. Others need continuing treatment because inflammation remains active.

A smaller group develops a clearer pattern of lupus, systemic sclerosis, inflammatory myositis, or rheumatoid arthritis over time. This may lead to a change in the diagnosis or treatment plan. It does not necessarily mean the original diagnosis was wrong; overlap conditions can evolve.[3,5]

For many people, care consists of outpatient appointments, periodic blood tests, and checks of heart and lung function. Work, study, exercise, travel, and family life can remain possible, although fatigue, pain, cold sensitivity, or appointments may require adjustments.

Gentle strengthening and aerobic activity can help maintain muscle function and fitness. During a flare, activity may need to be reduced and built up gradually. A physiotherapist or occupational therapist can suggest ways to protect painful joints and manage daily tasks.

Pregnancy is possible for many people with MCTD, but planning matters. Disease activity, pulmonary hypertension, and some medicines can affect pregnancy safety. A medication review and specialist discussion should take place before trying to conceive. Do not stop prescribed treatment without medical advice.

Long-term outlook is generally better when major lung and heart complications are absent. Pulmonary hypertension and progressive lung disease have the greatest effect on health and survival, so routine screening and prompt assessment of new breathing symptoms are important.[2,5]

When to get medical help

Arrange routine medical follow-up if your usual symptoms are becoming more frequent, a medicine is causing problems, or daily activities are getting harder. New reflux, swallowing difficulty, finger sores, joint swelling, muscle weakness, cough, or reduced exercise capacity should also be assessed.

Seek urgent medical advice for:

Call emergency services for severe breathing difficulty, fainting, sudden heavy or crushing

chest pain, blue or grey lips, new one-sided weakness, or a severe allergic reaction. These symptoms may have causes other than MCTD, but they require immediate assessment.

- New or rapidly worsening shortness of breath
- Chest pain, especially with breathing or activity
- Dizziness, fainting, or new ankle swelling
- A painful finger or toe that remains blue, pale, or develops a sore
- Fever or other signs of infection while taking immune-suppressing medicine
- New difficulty swallowing liquids or repeated choking

Common questions

Is mixed connective tissue disease the same as lupus?

No. MCTD can cause lupus-like symptoms, but it also has features associated with systemic sclerosis and inflammatory myositis. Blood test patterns and the overall combination of symptoms help distinguish them.

Can mixed connective tissue disease go away?

MCTD is considered a long-term condition. Symptoms may become quiet for months or years, but this is not the same as a permanent cure. Ongoing monitoring may still be needed during symptom-free periods.

Does a positive anti-U1 RNP test mean I have MCTD?

Not by itself. Anti-U1 RNP antibodies can occur in other autoimmune conditions. Diagnosis requires a compatible clinical pattern, examination findings, and assessment for other explanations.

What foods should I avoid with MCTD?

No specific diet has been proven to treat MCTD. If reflux is a problem, smaller meals and avoiding foods that trigger your symptoms may help. A balanced diet is also useful for heart and bone health, particularly during corticosteroid treatment.

Can MCTD affect my life expectancy?

Many people live for years with manageable symptoms. The outlook is more serious when pulmonary hypertension, progressive lung scarring, or major heart involvement develops. Individual outlook is based more on organ involvement than on antibody levels alone.[2,5]

Can I exercise with MCTD?

Often, yes. Regular movement can support strength, joint mobility, mood, and heart health. The type and amount may need adjustment during muscle inflammation, active arthritis, lung symptoms, or a flare.

Sources

- Merck Manual Consumer Version. "Mixed Connective Tissue Disease (MCTD)." Merck & Co.
- Gunnarsson R, Hetlevik SO, Lilleby V, Molberg Ø. "Mixed connective tissue disease." Best Practice & Research Clinical Rheumatology . 2016;30(1):95-111.
- Tani C, Carli L, Vagnani S, et al. "The diagnosis and classification of mixed connective tissue disease." Journal of Autoimmunity . 2014;48-49:46-49.
- Humbert M, Kovacs G, Hoeper MM, et al. "2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension." European Heart Journal . 2022;43(38):3618-3731.
- Hajas A, Szodoray P, Nakken B, et al. "Clinical course, prognosis, and causes of death in mixed connective tissue disease." Journal of Rheumatology . 2013;40(7):1134-1142.
- National Organization for Rare Disorders. "Mixed Connective Tissue Disease." NORD Rare Disease Database .